Acer Therapeutics Inc is a pharmaceutical company, developing and commercializing cell therapies for several major diseases.In July 2017, Acer Therapeutics and Opexa Therapeutics had entered into a definitive merger agreement under which the stockholders of Acer were estimated to become holders of approximately 88.8% of Opexa's outstanding common stock. Existing stockholders of Acer, as well as investors in Acer's concurrent financing, would receive newly issued shares of Opexa common stock in connection with the proposed merger. Following the closing of the proposed merger, the current Opexa shareholders were expected to own approximately 11.2%, the current Acer stockholders were expected to own approximately 63.8%, and the investors participated in the concurrent financing were expected to own approximately 25%. After the completion of the transaction, Opexa's name would be changed to Acer Therapeutics Inc, and Opexa intended to apply to change its ticker symbol on the NASDAQ Capital Market to "ACER." A